Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. reported an insider share transfer involving its President and CFO, Andrew Guggenhime. On 01/14/2026, 61,850 shares of common stock were moved from his direct holdings to ALG 2025 GRAT HOLDINGS LLC at a reported price of $0 per share. The filing notes that he is the sole member and manager of this LLC, and that the LLC is wholly owned by a grantor retained annuity trust for which he is the sole annuitant and trustee.
After the transaction, Guggenhime directly held 62,459 shares of Vaxcyte common stock and indirectly held 61,850 shares through ALG 2025 GRAT HOLDINGS LLC.
Vaxcyte, Inc. director Olivier Brandicourt reported receiving new equity awards. On January 15, 2026, he was granted 1,357 shares of Common Stock underlying restricted stock units, which will fully vest on the earlier of June 12, 2026 or the day before the next annual stockholder meeting, subject to his continuous service.
He was also granted a stock option for 6,750 shares of Common Stock, which vests monthly and will be fully vested on the same schedule, also conditioned on continued service. After the RSU grant, he directly beneficially owned 2,505 shares of Common Stock, and he held 6,750 stock options.
Vaxcyte (PCVX) reported Q3 2025 financial results. The company posted a net loss of $212.8 million, driven by higher operating expenses as R&D rose to $209.9 million and G&A reached $32.4 million. Year-to-date, net loss was $520.1 million.
Liquidity remains strong with $2.67 billion in cash, cash equivalents and investments as of September 30, 2025 (cash and cash equivalents $281.1 million, short‑term investments $1.43 billion, long‑term investments $959.3 million). Operating cash use totaled $430.7 million for the first nine months.
Vaxcyte expanded manufacturing capacity and supply: it maintains a long‑term arrangement with Lonza and, on September 24, 2025, entered a 15‑year commercial manufacturing agreement with Thermo Fisher for drug product. Non‑cancelable purchase commitments to key manufacturing partners totaled $631.7 million. Shares outstanding were 130,029,111 at September 30, 2025 and 130,906,263 at October 31, 2025.
Vaxcyte, Inc. (PCVX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company states the information in Items 2.02 and 9.01, including Exhibit 99.1, is furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act. Vaxcyte’s common stock trades on The Nasdaq Stock Market LLC under the symbol PCVX.
Vaxcyte, Inc. entered into a long-term Master Services Agreement with Patheon Manufacturing Services, part of Thermo Fisher Scientific, effective September 24, 2025. Patheon will formulate, fill, package, test, manufacture and supply Vaxcyte’s drug product from its Greenville, North Carolina facility.
The agreement includes binding minimum purchase commitments over defined forecast periods at established prices that may be adjusted, along with payments for technology transfer and reimbursement of certain capital expenditures. It has an initial 15-year term and automatically renews for additional three-year periods unless either party gives notice.
Vaxcyte can terminate for convenience or for specified causes, and either party may terminate for insolvency events, uncured legal or regulatory violations, or uncured material breach. If Vaxcyte terminates for convenience, it must pay Patheon at least a fixed amount in the mid-eight-figures or an amount tied to the current forecast plus certain capital commitments, with a different formula applying in the case of a defined Program Failure.
Vaxcyte, Inc. entered into a long-term Master Services Agreement with Patheon Manufacturing Services, part of Thermo Fisher Scientific, effective September 24, 2025. Patheon will formulate, fill, package, test, manufacture and supply Vaxcyte’s drug product from its Greenville, North Carolina facility.
The agreement includes binding minimum purchase commitments over defined forecast periods at established prices that may be adjusted, along with payments for technology transfer and reimbursement of certain capital expenditures. It has an initial 15-year term and automatically renews for additional three-year periods unless either party gives notice.
Vaxcyte can terminate for convenience or for specified causes, and either party may terminate for insolvency events, uncured legal or regulatory violations, or uncured material breach. If Vaxcyte terminates for convenience, it must pay Patheon at least a fixed amount in the mid-eight-figures or an amount tied to the current forecast plus certain capital commitments, with a different formula applying in the case of a defined Program Failure.
Elvia Cowan, SVP Finance at Vaxcyte, Inc. (PCVX), reported the disposition of 482 shares of the issuer's common stock on 09/08/2025 at a reported price of $32.41 per share. The filing shows 26,156 shares were beneficially owned by the reporting person after the transaction and identifies the ownership form as direct.
The form explains these 482 shares were surrendered to the company to satisfy tax-withholding obligations arising when restricted stock units vested. The Form 4 was signed on behalf of Elvia Cowan by an attorney-in-fact on 09/10/2025.
Harpreet S. Dhaliwal, listed as Chief Technical Ops Officer and a director/officer of Vaxcyte, Inc. (PCVX), reported the surrender of 1,204 shares of common stock on 09/08/2025. The transaction is coded "F" and reflects shares surrendered to the issuer to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). The reported price per share for the disposition is $32.41. Following the transaction, Dhaliwal beneficially owned 33,670 shares, held directly. The Form 4 was signed on behalf of Dhaliwal by an attorney-in-fact on 09/10/2025. The filing was made by a single reporting person.
Vaxcyte, Inc. (PCVX) insider change: Chief Operating Officer Wassil Jim reported transactions dated 09/08/2025 showing a disposition of 2,759 shares of common stock at $32.41 per share, recorded as surrendered shares to cover tax withholding on vested restricted stock units. After the reported transactions, the filing states the reporting person beneficially owned 141,848 shares. The filing also discloses a separate transfer: on 09/09/2025 the reporting person transferred 1,663 shares to an ex-spouse under a divorce settlement reflected as a domestic relations order, and those transferred shares will not be reported as beneficially owned in future Section 16 filings.
Insider transaction at Vaxcyte, Inc. (PCVX): The reporting person, Andrew Guggenhime (President and CFO), recorded a disposition of 2,890 shares of Vaxcyte common stock on 09/08/2025 at a price of $32.41 per share. After the transaction, Mr. Guggenhime beneficially owned 124,309 shares. The filing explains these shares were surrendered to the issuer to cover applicable tax withholding obligations arising when restricted stock units vested, indicating the transfer was related to tax withholding rather than an open-market sale. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Grant Pickering, who is both Chief Executive Officer and a director of Vaxcyte, Inc. (PCVX), reported a transaction on 09/08/2025 in a Form 4 filing. The filing shows 7,356 shares of common stock were disposed of at $32.41 per share; the explanation states these shares were surrendered to the issuer to cover tax withholding when restricted stock units vested. After the reported transaction, Mr. Pickering beneficially owned 500,908 shares directly. The filing also discloses two trusts holding 136,215 shares each for his son and daughter. The Form 4 was signed on 09/10/2025 by an attorney-in-fact.